Press release

September 2017

FDA Acknowledges Receipt Of Sorrento Therapeutics Inc, NDA For ZTlido™; PDUFA Date Set For February 28, 2018

September 12, 2017

SAN DIEGO, Sept. 12, 2017 /PRNewswire/ — Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”), announced today that SCILEX Pharmaceuticals Inc. (“SCILEX”), a majority-owned subsidiary of Sorrento, has received from the U.S. Food and Drug Administration (“FDA”) acknowledgement of receipt of its recently resubmitted New Drug Application (“NDA”) for ZTlido™ (lidocaine patch 1.8%) which has been considered a … Continue reading FDA Acknowledges Receipt Of Sorrento Therapeutics Inc, NDA For ZTlido™; PDUFA Date Set For February 28, 2018
X

Share This Page

XS SM MD LG XL